Search →

Overview

Investing In a Better Future

If you’ve come to this page, we hope you are as excited about Bicycle as we are. Our goal is to be one of the world’s leading solid tumor therapeutics companies. Please give us a call or send us an email if you have questions about our science, clinical programs, strategy or any other aspect of the Bicycle story.

Presentation

01/13/25
January 2025 Corporate Deck
Press
Date
Title
Date
01/13/25
Title
Bicycle Therapeutics Announces Updated Topline Zelenectide Pevedotin Data and Highlights 2025 Strategic Priorities and Milestones
Date
01/09/25
Title
Bicycle Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
Date
01/03/25
Title
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Date
12/12/24
Title
Bicycle Therapeutics Announces Data Updates Across Zelenectide Pevedotin Program and Development Strategy Leveraging NECTIN4 Gene Amplification
Overview →Stock Information →SEC Filings →Annual General Meeting →UK Annual Reports →Governance + Leadership →Presentation + Events →Analyst Coverage →Press Releases →Investor Resources →

Search